Podcasts about Lung

Study Discovers Increased Cancers After MRNA Vaccines, Bret Weinstein- Covid & mRNA: Harms and Damages Exposed Bret Weinstein- Covid & mRNA: Harms and Damages Exposed (NEW!) REMINDER: CDC Didn't Track VAERS Safety Signals John Campbell- Increased cancers after mRNA vaccines   Study- Covid & mRNA: Harms and Damages Exposed (NEW!) | DarkHorse https://youtu.be/zkrbZmYuRoY?si=_0yO0y5ftLacoVJ1 Bret Weinstein 512K subscribers 25,699 views Sep 5, 2025 A new article on the harms and hazards of both SARS-CoV2 and the mRNA biologics said to counter the virus. Full Episode: https://youtube.com/live/wQWkKrM3Dt8 Mentioned in this segment: Zywiec et al 2025. COVID-19 Injections: Harms and Damages, a Non-Exhaustive Conclusion. Journal of American Physicians and Surgeons, 30(3): https://jpands.org/vol30no3/zywiec.pdf ***** Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.com Heather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.com Our book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned) Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org   REMINDER: CDC Didn't Track VAERS Safety Signals | DarkHorse https://youtu.be/u3UAyr6s7xc?si=VUoenskCyMdViArS Bret Weinstein 512K subscribers 16,906 views Sep 5, 2025 RFK Jr. fires the new director, after which other CDC officials resign, and eight former directors of the CDC pen a letter to the New York Times arguing that Kennedy is a hazard to our health. Bret Weinstein and Heather Heying discuss "The Plot Against Kennedy" in Episode 292 of The Evolutionary Lens. Full Episode: https://youtube.com/live/wQWkKrM3Dt8 Mentioned in this segment: NYT op-ed #2 from former CDC directors: We Ran the C.D.C.: Kennedy Is Endangering Every American's Health: https://www.nytimes.com/2025/09/01/op... Bret and Heather 132nd DarkHorse Podcast Livestream: 50 States not in a Roe https://youtube.com/live/usP2D_qGUZs CDC didn't monitor VAERS for COVID safety signals (June 2022): https://childrenshealthdefense.org/de...   Increased cancers after mRNA vaccines Watch this video at- https://youtu.be/3dnIGqUlluc?si=sDbAdXTgOsCiCLev Dr. John Campbell 3.25M subscribers 143,152 views Sep 5, 2025 COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province https://pubmed.ncbi.nlm.nih.gov/40881... https://pmc.ncbi.nlm.nih.gov/articles... https://www.thefocalpoints.com/p/brea... The rate of first hospitalization for cancer of any site Unvaccinated group: 0.85% Vaccinated group (one or more doses): 1.15% N = 296,015 population Hospital admission with a cancer diagnosis, 3,124 (p less than 0.001). Vaccination with at least one dose Colon-rectal cancer HR: 1.34 Breast cancer HR: 1.54 Bladder cancer HR: 1.62 After three or more vaccine doses Breast cancer HR: 1.36 Bladder cancer HR: 1.43 All significant After one dose (180 days after) Rate of first hospital admissions for cancers All cancers: up 23% significant Colorectal: up 34% significant Lung: down = 10% Breast: up 54% significant Uterine: up = 75% Ovarian: up = 65% Prostate: up = 1% Bladder: up 62% significant Thyroid: up =58% Haematological: up = 33% After three dose (180 days after administration of third dose) All cancers: up = 9% Colorectal: up = 14% Lung: down = 5% Breast: up=36% significant Uterine: up = 20% Ovarian: up = 86% Prostate: down = 3% Bladder: up=43% significant Thyroid: down = 3% Haematological: up = 5% More about the study Population-wide cohort analysis Evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. National Health System official data, entire population, Pescara province, Italy Followed from June 2021 (six months after the first vaccination) to December 2023. 296,015 residents aged ≥11 years Hospital admission with a cancer diagnosis, 3,124 16.6% were unvaccinated 83.3% received ≥1 dose 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death Cancer hospitalization was significant only among the subjects with no previous SARS-CoV-2 infection Some cancer risks went down after 1 year (relative to 180 days) (But breast, ovarian and bladder went up at one year relative to 180 days after 1 vaccine dose) Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.  

Join us for an in-depth conversation with Dr. Aahd Kubbara, a practicing pulmonologist, intensivist, and Assistant Professor of Medicine at the University of Minnesota Medical Center. Dr. Kubbara specializes in pulmonary, allergy, critical care, and sleep medicine, with advanced expertise in interstitial lung disease, asthma, and targeted biological therapies. In this episode, we explore the complexities of lung health and the latest strategies for preventing and managing chronic respiratory conditions: ·       How inflammatory lung diseases can cause long-term scarring. ·       The consequences of untreated or poorly managed asthma over time. ·       What pulmonary fibrosis is and the most effective approaches to treatment. ·       The risks of normalizing chronic respiratory symptoms. ·       Seasonal asthma triggers and how to reduce their impact. With years of experience at the Mayo Clinic and University of Nevada, as well as community pulmonary care practice, Dr. Kubbara offers insights into cutting-edge therapies, personalized medicine, and preventive strategies to maintain lung health. Learn more about Dr. Kubbara and his work in pulmonary medicine here! Episode also available on Apple Podcasts: https://apple.co/38oMlMr  Keep up with Dr. Aahd Kubbara socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en  X : https://x.com/aahdkubbara 

Microplastics were found to trigger cancer-like changes in healthy lung cells, including increased mobility, DNA damage, and activated survival pathways Inhaled particles bypass your body's defenses and embed deep in your lungs, where they silently disrupt cellular function without causing obvious inflammation A review of 31 studies confirmed that microplastics harm your lungs, gut, and reproductive organs even at exposure levels that mimic everyday life Smaller nanoplastics are especially dangerous because they cross into your bloodstream, reaching your liver, brain, and other organs where they cause long-term damage Natural strategies like psyllium, chitosan, probiotics, and autophagy-enhancing nutrients help trap and remove plastic particles before they're absorbed

Lung cancer remains one of the leading causes of cancer-related death, yet many cases occur in people who have never smoked. One often-overlooked culprit is radon, a naturally occurring radioactive gas and the second leading cause of lung cancer.

Episode 90: Breathing New FuturesThe latest Nursing Australia News (03:00) Global nurse equity, Aussie prescribing breakthrough, and tap water fentanyl scandal.Happy Birthday Matthew! (04:30) Lung Cancer Screening (05:55) Lung cancer is still Australia's leading cause of cancer death, but a new national screening program promises to shift the landscape. So, what does this mean for practice, and how can nurses prepare to support patients through it? Matt speaks with Mel Laan, the Lung Cancer Nurse Consultant from Royal Adelaide Hospital, to find out. Sam - the APNA Nurse Scholar (16:15) APNA Nurse Scholar Sam takes us inside her journey — from the wards of Australia to a global classroom in London. We'll hear what she learned, what inspired her, and how the experience is shaping her nursing practice.This episode is sponsored by Health Professionals Bank. It takes passion and dedication to be a healthcare professional. Every day you go above and beyond to treat, care for and help others in their time of need. That's why at Health Professionals Bank, we believe you deserve a bank that cares about you and helps keep your finances healthy throughout your life. (Membership, responsible lending criteria and Terms and Conditions apply. Health Professionals Bank is a division of Teachers Mutual Bank Limited ABN 30 087 650 459 AFSL/Australian Credit Licence 238981.)National Nursing Clinical Placements Program Campaign APNA Workforce Survey - Have YOUR SAY!  Health Professionals Bank✨ Give Matt a birthday gift! Like & follow in Insta @saintmedaesthetics SAINT Medical Aesthetics Facebook; LinkedIn; National Lung Cancer Screening Program | Australian Government Department of Health, Disability and Ageing National Lung Cancer Screening Program – Healthcare provider toolkit | Australian Government Department of Health, Disability and Ageing Lung cancer screening resources | Australian Government Department of Health, Disability and Ageing National Lung Cancer Screening Program Health Workforce Education - Lung Foundation Australia National Lung Cancer Screening Program - NACCHO Click here to get in touch with Nursing Australia (send a text for free from anywhere in the world) #askusanything Hosted & Produced by: Matthew St Ledger & Leith Alexander Produced by: Leith Alexander & Matthew St Ledger

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung center Cardiologist Geurys Rojas-Marte, MD continue their conversation on how individuals can prevent or manage risk factors for heart failure. They also talk about the latest advancements in heart failure treatment at any stage.

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

Evening Prayer for Holiness and Healing #prayer #god #jesus #holyspirit #aimingforjesus #healing #Lung #lungcancer Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

This week, Johnny returned from a bad hotel, told us about the landlord at Gatwick, and quizzed Harry on his apple crumble and his nan-in-law. Hear Johnny on Radio X every weekday at 4pm across the UK on digital radio, 104.9 FM in London, 97.7 FM in Manchester, on Global Player or via www.radiox.co.uk

Send us a textWhat if AI could predict cancer outcomes better than traditional methods—and at a fraction of the cost? In this episode, I explore how multimodal AI is reshaping lung and prostate cancer predictions and why integration challenges still stand in the way.Episode Highlights with Timestamps:[00:02:57] Agentic AI in toxicologic pathology – what it is and how it could orchestrate workflows.[00:05:40] Grandium desktop scanners – making histology studies more accessible and efficient.[00:08:03] Clover framework – a cost-effective multimodal model combining vision + language for pathology.[00:13:40] NSCLC study (Beijing Chest Hospital) – AI predicts progression-free and overall survival with high accuracy.[00:17:58] Prostate cancer prognostic model (Cleveland Clinic & US partners) – validating AI-enabled Pathomic PRA test.[00:23:35] Thyroid neoplasm classification – challenges for AI in distinguishing overlapping histopathological features.[00:34:49] Real-world Belgium case study – AI integration into prostate biopsy workflow reduced IHC testing and turnaround time.[00:41:03] Lessons learned – adoption hurdles, system integration, and why change management is essential for successful digital transformation.Resources from this EpisodeWorld Tumor Registry – A global open-access repository for histopathology images: World Tumor RegistryBeijing Chest Hospital NSCLC AI Prognostic Study – Prognosis prediction using multimodal models.Cleveland Clinic Pathomic PRA Study – Independent validation of AI-enabled prostate cancer risk assessment.Grandium Scanners – Compact desktop scanners for histology slides: Grandium.aiSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Good Morning,Nan tho tha hna maw? Tuzing zong morning devotion i hrawm ti dingin kan in sawm hna. A kan hruaitu: Rev. Ram MaungTitle: Na Lung Dong HlahLunglawmhnak ngan pi he,CAPT: CEBC Arts Production Team--Music By Peder B. Helland

Show Notes 22 August 2025Story 1: Zapping Volunteers' Brains with Electricity Boosted Their Math SkillsSource: ScienceAlert.comLink: https://www.sciencealert.com/zapping-volunteers-brains-with-electricity-boosted-their-maths-skillsStory 2: Moon mining takes giant leap forward with plans to harvest lunar soilSource: Newsweek via MSNLink: https://www.msn.com/en-us/money/markets/moon-mining-takes-giant-leap-forward-with-plans-to-harvest-lunar-soil/ar-AA1JFqd9Story 3: University of British Columbia researchers create 3D-printed living lung tissue - Printed tissue enables better testing of drugs and disease pathwaysSource: University of British Columbia websiteLink: https://news.ok.ubc.ca/2025/07/15/ubco-researchers-create-3d-printed-living-lung-tissue/Story 4: AI designs molecular missiles to precisely target cancer cellsLink: https://www.dtu.dk/english/newsarchive/2025/07/ai-platform-designs-molecular-missiles-to-attack-cancer-cellsHonorable MentionsStory: AI-powered microscope predicts, and tracks protein aggregation linked to brain diseasesSource: EPFL NewsLink: https://actu.epfl.ch/news/smart-microscope-captures-aggregation-of-misfold-2/Story: Rolls-Royce teams up for advanced modular nuclear reactors to power 3 million homesSource: InterestingEngineering.comLink: https://www.msn.com/en-us/money/smallbusiness/rolls-royce-teams-up-for-advanced-modular-nuclear-reactors-to-power-3-million-homes/ar-AA1JOpTmStory: Cells Outside the Brain Show Signs of Memory And "Learning" For the First TimeSource: IFL ScienceLink: https://www.iflscience.com/cells-outside-the-brain-show-signs-of-memory-and-learning-for-the-first-time-7945Story: A New Hidden State of Matter Could Make Computers 1,000x FasterSource: Popular MechanicsLink: https://www.popularmechanics.com/science/a65531679/hidden-metallic-state/

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Luke Williams, a cardiothoracic surgery trainee at Royal Papworth Hospital, NHS Blood and Transplant Clinical Research Fellow, and a PhD student at Cambridge University in the UK. Luke discusses his paper, “The United Kingdom's experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes.”   The discussion explores: Requirements, regulations, and practices in the UK around DCD procurement and A-NRP How survival rates differ and what they might imply about primary graft dysfunction in DCD versus DBD Further work planned in the area in the UK and throughout Europe For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

In this episode of the PFC Podcast, Dennis and Alex delve into the topic of forced vital capacity in the context of chest trauma. They discuss a research paper that explores the assessment of forced vital capacity for risk stratification of blunt chest trauma patients in emergency settings. The conversation covers the importance of understanding chest wall injuries, clinical guidelines for treatment, challenges in diagnosing rib fractures, and the implications of the study's findings on patient outcomes and resource allocation in military medicine.TakeawaysForced vital capacity is crucial for assessing chest trauma.Chest wall injuries can significantly impact patient outcomes.Pain management is a key component of treatment strategies.Clinical guidelines help in managing chest injuries effectively.Risk stratification is essential for resource allocation in trauma care.The study highlights the importance of forced vital capacity measurements.Understanding patient dispositions is vital in emergency settings.Challenges exist in diagnosing rib fractures in the field.The study's methodology raises questions about its applicability.Future research is needed to refine treatment approaches for chest trauma.Chapters00:00 Introduction to the Podcast00:30 Exploring Forced Vital Capacity02:02 Understanding Chest Trauma04:56 The Importance of Chest Wall Injuries08:37 Clinical Guidelines and Treatment Algorithms10:21 Challenges in Diagnosing Rib Fractures12:33 Pain Management and Treatment Strategies16:25 Dispositions and Resource Allocation19:02 Risk Stratification in Chest Injuries22:39 Forced Vital Capacity and Its Relevance27:16 Study Overview and Methodology32:29 Outcomes and Implications of the Study36:41 Critical Analysis of the Research46:38 Reflections on the Study's Impact52:12 Conclusion and Future DirectionsFor more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠⁠

Send us a textDiaphragm Position on Chest Radiograph to Estimate Lung Volume in Neonates.Dahm SI, Sett A, Gunn EF, Ramanauskas F, Hall R, Stewart D, Koeppenkastrop S, McKenna K, Gardiner RE, Rao P, Tingay DG.JAMA Pediatr. 2025 Jul 21:e252108. doi: 10.1001/jamapediatrics.2025.2108. Online ahead of print.PMID: 40690243 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Authors: Justin Ellenberg, MD; Latha Panchap, MD; Zia Siddiqui, MD; and Babar Fiza, MD Section Editor: Yuriy Bronshteyn, MD

Lung cancer, particularly non-small cell lung cancer (NSCLC), is the deadliest cancer worldwide. Cigarette smoking is one of the main causes, but not every smoker develops the disease. This suggests that other biological factors help determine who develops cancer. Researchers from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis, and from the Richard L. Roudebush Veterans Affairs Medical Center have now found that cigarette smoke, combined with a weakened DNA repair system, can trigger the early stages of lung cancer, particularly NSCLC. This work, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, was recently published in Volume 16 of Oncotarget. Full blog - https://www.oncotarget.org/2025/08/11/cigarette-smoke-and-weak-dna-repair-a-double-hit-behind-lung-cancer-risk/ Paper DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Video short - https://www.youtube.com/watch?v=UEiCz834a8c Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This month KYW Newsradio's Rasa Kaye and Deborah Heart and Lung center Cardiologist Geurys Rojas-Marte, MD discuss how individuals can prevent or manage risk factors for heart failure. They also talk about the latest advancements in heart failure treatment at any stage.

Lung cancer remains one of the deadliest cancers in the United States, in part because it’s often detected too late. On The Spark, UPMC Thoracic Surgeon Dr. Troy Moritz joined the show to shed light on who should be screened, what symptoms not to ignore, and how technology is changing the way lung cancer is detected and treated. Who Should Be Screened? Dr. Moritz emphasized the importance of lung cancer screenings for a specific group:“We’re looking for people that are age 50 to up to 80 years of age and those people that have smoked what we consider to be 20 pack years,” he explained.That includes anyone who smoked a pack a day for 20 years — or an equivalent amount — and hasn’t quit within the last 15 years. These high-risk individuals are encouraged to undergo low-dose CT scans, which Dr. Moritz described as simple and noninvasive.“It’s pretty much just get in the CAT scan machine and buzz in, buzz out,” he said. “It’s not an MRI, so you don’t have to worry about that claustrophobic feeling.”Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Eco-Business spoke to Hang Lung Properties deputy director of sustainability John Haffner for the latest episode of On the frontlines, which profiles change-makers on the hard edge of sustainable business. Tune as we discuss: Discipline and sustainability spending Are our sustainability targets too weak or too ambitious? How do you justify your job? Managing greenwashing risk Advice for sustainability aspirants Burnout risk

Full article: https://www.ajronline.org/doi/10.2214/AJR.25.33063 Bardia Nadim, MD, discusses the AJR article by Jang et al. exploring real-world results from the use of AI for detecting lung metastases from colorectal cancer.

A new NEJM trial found methotrexate offers similar lung function improvements as prednisone in pulmonary sarcoidosis, but with fewer side effects—suggesting it could be a safer first-line option for some patients. A JAMA study revealed that patients trust physicians less when AI is mentioned in care ads, highlighting the importance of framing AI as a tool that supports—not replaces—clinical judgment. Another NEJM trial showed that giving take-home ondansetron to children after ED visits for gastroenteritis significantly reduced vomiting and return visits, with no added risks. Together, these studies support a shift toward individualized care, better patient communication, and practical interventions to improve outcomes.

In today's episode, we connect with Dr. Aahd Kubbara to discuss the intricacies of lung function and targeted biological therapies for asthma. Dr. Kubbara is a practicing pulmonologist and intensivist at the University of Minnesota Medical Center, where he also serves as an Assistant Professor of Medicine, Pulmonary, Allergy, Critical Care, and Sleep and Associate Program Director of the Pulmonary and Critical Care Fellowship. Hit play to discover: The types of inflammatory diseases that can lead to lung scarring. The consequences of untreated asthma over years of time. What pulmonary fibrosis is, and how to treat it. The potential impacts of normalizing chronic health symptoms. How seasonal asthma is typically triggered and how to mitigate it. Dr. Kubbara brings a wealth of experience to his field, including a year in Critical Care at the Mayo Clinic in Rochester, and another year in Academic Pulmonary and Critical Care at the University of Nevada, Reno. He also spent a year practicing community Pulmonary and Critical Care at both Mayo Clinic Eau Claire and Aspirus Wausau Hospital. In addition, he completed an advanced fellowship in Interstitial Lung Disease and Vasculitis at the Mayo Clinic. To learn more about Dr. Kubbara and his work, click here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C Keep up with Julian R. Gershon Jr. socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en  X : https://x.com/aahdkubbara 

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available from July 1 that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities. - 肺がんは、オーストラリアで5番目に多く診断されているがんですが、発見が遅れることが多く、がんによる死亡原因の中で最も多くなっています。こうした中、7月1日から新たな肺がんの検診プログラムが始まりました。

Tune in as Alec, Mengyu, Parisa, Ethan, and Ibrahim dissect a case  of a 40 YO M presenting after a motor vehicle collision!  Download CPSolvers App here RLRCPSOLVERS

Microbiome is a mysterious medical frontier with more questions than answers. In this episode, nutrition expert Neal Barnard, MD, of George Washington University explores the connection between diet, gut microbiome and lung health. While fiber and plant-based diets have been shown to shape a healthier microbiome, this conversation sheds light on the growing evidence that what we eat may have far-reaching effects beyond the gut—including in our lungs.

Talking Fantasy Football on The Kenny & JT Show with our good friend Bob Lung from Big Guy Fantasy Sports and bigguyfantasysports.com.

Dr. Mohleen Kang chats with Dr. Anna Podolanczuk and Dr. Gary Hunninghake about their article, "Approach to the Evaluation and Management of Interstitial Lung Abnormalities."

In this episode, I sit down with C. Vivek Lal, MD, FAAP, a physician-scientist and the founder & CEO of Resbiotic, to explore the incredible connection between our gut microbiome and respiratory health.  Dr. Lal shares how his clinical work with premature infants inspired a deeper dive into gut-lung science, ultimately leading to the development of Resbiotic—a science-first wellness brand that's bridging the gap between clinical research and everyday health. What really struck me in this conversation was Vivek's blend of curiosity, care, and credibility. He's not just creating a product—he's on a mission to help people breathe easier, live better, and understand how their gut health plays a role in it all. If you're interested in functional wellness, biotech innovation, or just want to understand your body a bit better, this one is for you. Here are a few highlights from our conversation: * The gut-lung axis: what it is and why it matters * How a NICU doctor became a CPG founder * Why Resbiotic leads with clinical credibility, not marketing fluff * The challenge of translating deep science into consumer products * How education and transparency are building trust in a skeptical market Join me, Ramon Vela, as I listen to the episode and discover how science, storytelling, and heart are driving the next wave of health and wellness innovation. For more on Resbiotic, visit: https://resbiotic.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review.  Plus, don't forget to follow us on Apple and Spotify.  Your support helps us bring you more content like this! * Today's Sponsors: Color More Lines: https://www.colormorelines.com/get-started Color More Lines is a team of ex-Amazonians and e-commerce operators who help brands grow faster on Amazon and Walmart. With a performance-based pricing model and flexible contracts, they've generated triple-digit year-over-year growth for established sellers doing over $5 million per year.   Use code "STORY OF A BRAND” and receive a complimentary market opportunity assessment of your e-commerce brand and marketplace positioning.    1 Commerce: https://1-commerce.com/story-of-a-brand Scaling a DTC brand becomes harder the bigger you grow, especially when you're limited to selling on just one channel.  While you're focused on day-to-day ops, your competitors are unlocking marketplaces like Amazon, Walmart, and even retail shelf space—and capturing customers you're missing. That's where 1-Commerce comes in.  They help high-growth brands expand beyond their sites, handle end-to-end fulfillment, and scale through a revenue-share model that means they only win when you do.  As a Story of a Brand listener, you'll get one month of free storage and a strategy session with their CEO, Eric Kasper.

On this episode of Translating Proteomics, Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover:Needs in plasma proteomicsHow proteomics impacts drug development – with special guest Don Kirkpatrick Ph.D.!How lifestyle impacts the proteomeHow the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer's disease researchReferencesShome et al., 2022 - Serum autoantibodyome reveals that healthy individuals share common autoantibodieshttps://www.sciencedirect.com/science/article/pii/S2211124722006489LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health.Sylman et al., 2018 - A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patientshttps://www.nature.com/articles/s41598-018-25019-1Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology.Krönke et al., 2014 - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellshttps://www.science.org/doi/10.1126/science.1244851Seminal paper describing selective protein degradation caused by lenalidomide.Fink and Ebert 2015 - The novel mechanism of lenalidomide activityhttps://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activityReview of research elucidating the mechanisms of lenalidomide activityNdoja et al., 2025 - COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathwayhttps://www.mdpi.com/2073-4409/14/13/975Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradationSong et al., 2022 - RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacyhttps://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3KUse proteomics to discover that inavolisib acts through selective degradation of mutant PI3KαCanon et al., 2019 - The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityhttps://www.nature.com/articles/s41586-019-1694-1Covers the development of an inhibitor of KRAS mutant KRAS (G12C).Schneider et al., 2024 - Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axishttps://www.nature.com/articles/s42255-024-01108-6Review on the gut-brain axisWebpage for Johanna Lampe's Lab at Fred Hutch Cancer Center

Lung cancer has a high chance of relapse, so how do we get out of ahead of it? Nancy Guo, SUNY Empire Innovation Professor in the school of computing at Binghamton University, discusses technology that helps us do so. Nancy Guo is one of the newest additions to the Binghamton University School of Computing as […]

The boys are back with another outstanding guest. The King of Consistency Bob Lung is in the house to iron out who to draft based on consistency, who are some players carrying red flags, and where there is hidden value in 2025. This is not a show you want to miss as we gear up getting you ready for 2025.And... stay tuned until the very end as we drop a very special surprise!!Bob's Guide can be found here Hosted on Acast. See acast.com/privacy for more information.

In this episode, hosts Kyle Kruse and Richard Meiklejohn are joined by Doug Evans, CEO of Lungpacer, to discuss innovative breakthroughs in respiratory care. Doug outlines the critical issue of mechanical ventilation, which affects 2 million patients annually in the U.S., with a 40% mortality rate among them. He provides detailed insights into how Lungpacer's neurostimulation technology aims to improve patient outcomes by maintaining diaphragm muscle function, thereby reducing time on ventilators and minimizing the need for reintubation. The discussion covers the rigorous research and FDA approval process, as well as the forthcoming Aero Nova system designed to assist patients from the onset of mechanical ventilation. Doug also shares the company's plans for commercialization, manufacturing scale-up, and future clinical milestones. The conversation highlights the potential impact of Lungpacer's technology on patient survival rates and healthcare costs, positioning it as a transformative solution in critical care, a story sure to leave you informed and inspired.

About this episode: Asthma can cause sometimes debilitating symptoms for children who have it, and some—particularly Black and Hispanic children—can experience higher rates of diagnoses, hospitalizations and emergency department visits. In this episode: pediatrician and immunology researcher Dr. Elizabeth Matsui talks about the known causes behind childhood asthma and how it impacts youths, and how factors like poor housing conditions and barriers to care and medication worsen conditions and undermine long-term lung development. Guest: Dr. Elizabeth Matsui is a pediatric allergist-immunologist and epidemiologist and a leading researcher on the connection between asthma and environmental conditions. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: The Role of Neighborhood Air Pollution in Disparate Racial and Ethnic Asthma Acute Care Use—American Journal of Respiratory and Critical Care Medicine Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations—JAMA Do upper respiratory viruses contribute to racial and ethnic disparities in emergency department visits for asthma?—The Journal of Allergy and Clinical Immunology Tackling Housing Injustice—and Improving Childhood Asthma—Public Health On Call (June 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University

Australians at higher risk of lung cancer are being urged to take advantage of a new screening program that has launched this month. The scan will be free for patients under Medicare bulk-billing through GPs, with eligibility to be determined by age - those between 50 and 70 - and smoking history. It is the first new national cancer screening program in nearly 20 years. Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of cancer deaths because it is often diagnosed too late. SBS's Biwa Kwan spoke with Anita Dessaix from the Cancer Council, about the at-risk groups the program is targeting; and the goal to prevent over 12,000 deaths over a decade

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities.

We're getting by with our Collapsible Lung, and it's a good time 100% of the time... or is it? Take a breath and then take it in because we're covering Relient K's most controversial record. Does this episode have Disaster written all over it, or will we find this record Sweeter than we remember? Snap back, snap back, here we go again.If you like what you hear, please rate, review, subscribe, and follow!Connect with us here:Email: contact@churchjamsnow.comSite: https://www.churchjamsnow.com/IG: @churchjamsnowTwitter: @churchjamsnowFB: https://www.facebook.com/churchjamsnowpodcastPatreon: https://www.patreon.com/churchjamsnowpodcast

Granulomatosis with Polyangiitis (GPA) – Recognition and Management in the ED Hosts: Phoebe Draper, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/GPA.mp3 Download Leave a Comment Tags: Rheumatology Show Notes Background A vasculitis affecting small blood vessels causing inflammation and necrosis Affects upper respiratory tract (sinusitis, otitis media, saddle nose deformity), lungs (nodules, alveolar hemorrhage), and kidneys (rapidly progressive glomerulonephritis) Can lead to multi-organ failure, pulmonary hemorrhage, renal failure Red Flag Symptoms: Chronic sinus symptoms Hemoptysis (especially bright red blood) New pulmonary complaints Renal dysfunction Constitutional symptoms (fatigue, weight loss, fever) Workup in the ED: CBC, CMP for anemia and AKI Urinalysis with microscopy (hematuria, RBC casts) Chest imaging (CXR or CT for nodules, cavitary lesions) ANCA testing (not immediately available but important diagnostically) Management: Stable patients: Outpatient workup, urgent rheumatology consult, prednisone 1 mg/kg/day Unstable patients: High-dose IV steroids (methylprednisolone 1 g daily x3 days), consider plasma exchange, cyclophosphamide or rituximab initiation, ICU admission Conditions that Mimic GPA: Goodpasture syndrome (anti-GBM antibodies) TB, fungal infections Lung malignancy Other vasculitides (EGPA, MPA, lupus)

This Week: Catching Nathan Off Guard, Getting Dudes Drunk and Touching Their Junk, Churchy Reddit, In Utero Rules, Nathan Don't Practice Santeria, Songs About Pants, My Sweet Lord, Dr. Pepper, Choking to Death on Pull And Peel, A Single Skin Flap Keeping Us All Alive, Local Sexpot Dies, Blue Collar Comedy, Learn to Laugh At Yourself, The Two Popes. Recorded: 06/08/2025Get on the Patreon Train: https://patreon.com/Sushijackknife?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkBandcamp Store: https://sushijackknife.bandcamp.com/Email: sushijackknife@gmail.com

Since that first interview, Richard has faced multiple cancer recurrences—including brain tumors and cancer in his remaining lung—and continues to rely on cannabis oil as a central part of his healing. In this episode, he talks candidly about living with cancer, navigating the challenges of legalization, dealing with skeptical doctors, and staying grounded with family, humour, and positivity.00:37 – Introduction to Richard Lusk and his original interview from 201601:17 – How Richard first discovered his lung cancer02:45 – Starting cannabis oil and watching tumors shrink03:45 – Leaving Washington to care for his mother in Kansas—cannabis access cut off04:30 – Cancer returns and spreads to his brain05:38 – Returning to Washington for treatment and cannabis access06:10 – Telling his oncologist about cannabis oil07:02 – Doctors say it's incurable—Richard disagrees07:53 – How he takes a gram of cannabis oil each day08:54 – Symptoms that led to brain tumor discovery09:39 – Years in construction and staying physically resilient10:28 – Emotional vs. physical challenges of illness11:40 – Thoughts on legal cannabis access across the U.S.12:57 – Adrenal gland cancer and additional surgeries13:44 – Belief in cannabis over conventional treatments16:07 – The role of cannabis in surviving cancer17:40 – Advice for people newly diagnosed with cancer18:41 – Staying positive and the importance of family20:52 – Choosing your own path despite family opposition21:12 – Current restrictions and chemo side effects22:48 – Gratitude for life and simple pleasures23:26 – A brain surgeon's 6.5 rating and Richard's humour24:38 – Final thoughts, hope for change, and sharing his story Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

Tanzira Zaman, MD and Elizabeth Volkmann, MD, MS discuss the new official American Thoracic Society Clinical Statement on the diagnosis and management of interstitial lung abnormalities which Dr. Podolanczuk presented at ATS 2025.

282: If you suffer from asthma, allergies, chronic coughs, or are sensitive to smoke and pollution... heck, even if you have gut issues, this episode will blow your mind! I bet you didn't know that our gut health affects our lung health and vice versa! But think about it—if our gut impacts our brain, our skin, and even our mouth, why wouldn't it also affect our lungs? In fact, our lungs require certain probiotics that our gut does not, and that's exactly what we're diving into today: how to support our lungs by supporting our gut with specific probiotics and GLP-1-supporting products. Not GLP-1 drugs like Ozempic! These are natural products that support the GLP-1 our bodies already produce, without side effects. I'm joined by Kara from ResBiotic to help shed light on the connection between lung health, gut health, and weight management. Topics Discussed: → The gut-lung axis → Our lung microbiome → How SCFAs (short-chain fatty acids) aid in lung health → Where SCFAs come from → Probiotics for our lungs → Signs and symptoms of compromised lungs → Foods that support lung health → GLP-1 support → Why gut health influences weight loss or gain → How to lose weight by changing our gut microbiome As always, if you have any questions for the show please email us at digestthispod@gmail.com.  And if you like this show, please share it, rate it, review it and subscribe to it on your favorite podcast app.  Sponsored By: → resbiotic | https://resbiotic.com/ and use code DIGESTTHIS for 20% off Check Out Bethany: → Bethany's Instagram: @lilsipper → YouTube → Bethany's Website → Discounts & My Favorite Products → My Digestive Support Protein Powder → Gut Reset Book  → Get my Newsletters (Friday Finds)

Lung-protective ventilation (LPV), characterized by low tidal volumes and appropriate PEEP, is a cornerstone in managing patients with acute respiratory distress syndrome (ARDS). However, its application in patients with severe acute brain injury raises concerns. The potential for lung protective ventilation to increase intracranial pressure due to hypercapnia and elevated PEEP levels necessitates a closer examination of its safety and efficacy in this unique patient population.

ICYMI: Hour One of ‘Later, with Mo'Kelly' Presents – Thoughts on California's new weather tracking system that categorizes extreme heat factors, AND the latest in California's robotaxi expansion with the massive rollout of Volkswagens new autonomous vehicle fleet…PLUS – A look at California's ranking on the list of states with the healthiest lungs - on KFI AM 640…Live everywhere on the iHeartRadio app & YouTube @MrMoKelly

This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3012: Dr. Neal breaks down the role of genetics in cholesterol levels and explains how even those with a family history of heart disease can benefit from targeted lifestyle changes. From diet tweaks to exercise strategies, his practical tips empower listeners to take control of their heart health, no matter their DNA. Quotes to ponder: "HDL actually helps the body clear LDL from the arteries, which is why it's good." "One of the most effective ways to lower blood cholesterol and blood pressure quickly is weight loss." "Fiber is so helpful because it helps bind to cholesterol and helps the body get rid of it." Episode references: Omega-3 Fatty Acids (NIH Office of Dietary Supplements): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer USDA FoodData Central: https://fdc.nal.usda.gov/ National Heart, Lung, and Blood Institute: https://www.nhlbi.nih.gov Learn more about your ad choices. Visit megaphone.fm/adchoices